CTCPure Pitch Deck Teardown: A Placeholder Presentation

CTCPure: A Narrative-Heavy Approach to Cancer Diagnostics

The CTCPure pitch deck is a 14-slide presentation (with 7 slides provided for this analysis) that attempts to bridge the gap between complex oncology diagnostics and investor interest. The company’s tagline, "Remove the odds in cancer treatment selection," sets a high bar for a solution that aims to optimize how lung cancer is treated globally. However, the deck functions more as a problem-definition tool than a robust business case, leaving significant gaps in team expertise, competitive positioning, and financial requirements.

Slide 1: Title Slide

The title slide is minimalist, featuring the CTCPure logo and the primary value proposition: "Remove the odds in cancer treatment selection." The branding is simple, using a blue and yellow color scheme. While it establishes the sector (oncology/diagnostics), it provides no immediate indication of the company's stage or geographic location.

Slide 3: The Problem Storyboard

Slide 3 is the most visually dense slide in the deck, utilizing a four-panel comic strip to illustrate the patient journey. We follow a character named "Jack" through a three-week ordeal. In Week 1, Jack presents with a cough and chest pains and is prescribed antibiotics. By Week 2, his condition worsens (weight loss), leading to a hospital referral. By Week 3, after an MRI and CT scan, he finally undergoes a biopsy. The slide ends with the CTCPure logo next to a microscope icon, implying that their solution intervenes at this critical diagnostic juncture. This slide effectively communicates the lag time in current diagnostic protocols but does not yet explain how CTCPure shortens this window.

Slide 6: The Treatment Flowchart

This slide visualizes the current standard of care and its failures. The flowchart begins with "Cancer diagnosed" and "Treatment selected." It then branches into three outcomes: "Cancer not detectable" (leading to check-ups at 3, 6, and 12 months), "Cancer is reduced," and "Cancer has grown / remained similar." For the latter two, the slide highlights a critical pain point: "At least two weeks recovery before new treatment." This emphasizes the physical and temporal cost to the patient when the first-line treatment fails. The slide serves to validate the need for better initial treatment selection, which is the core of the CTCPure mission.

Slide 7: 4. Advantages + 5. Solutions

This slide introduces the technical nature of the product, though only in broad strokes. It lists three bullet points: "Innovative microfluidic solution," "Combining multiple and most recent insights for filtration," and "Not wasting money and time on ineffective treatments." This is the first mention of "microfluidics," suggesting the company is developing a hardware or lab-on-a-chip solution for filtering Circulating Tumor Cells (CTCs). However, the slide lacks any imagery of the device, data on filtration efficiency, or explanation of the "recent insights" mentioned.

Slide 8: 7. Traction (Financial Benefits)

Despite being titled "Traction," this slide focuses on market potential and cost savings rather than company milestones. It claims that "$2.3 billion can be saved for treatment of all lung cancer patients worldwide each year." It further specifies that this saving comes from ensuring "350.000 patients don’t get wrong treatment." While these figures are impressive, the deck does not provide a source for these calculations or explain how the $2.3 billion figure was derived. In a professional pitch, "Traction" should ideally refer to pilot programs, clinical trial phases, or partnerships, none of which are present here.

Slide 11: 9. Competition

Slide 11 is a significant red flag for any investor. Titled "9. Competition," it contains no data. Instead, it features a single sentence: "What are the alternative solutions to the problem you are trying to solve." This appears to be a placeholder from a template that the founders failed to fill in. In the highly crowded liquid biopsy and oncology diagnostic space, failing to acknowledge competitors like Guardant Health, Grail, or Adaptive Biotechnologies suggests a lack of market awareness.

Slide 13: 11. Investing

The final slide provided, titled "11. Investing," continues the trend of vagueness. It asks two questions: "What is your planned budget? What kind of budget are you looking for?" The response provided is: "We are looking at investment in information and funding for realisation of the products." It repeats the "$2.3 billion per year" figure and includes a generic graphic of two businessmen shaking hands. The slide fails to state a specific dollar amount, the equity offered, or the milestones the funding will achieve. This makes it impossible for an investor to evaluate the opportunity.

What Works in the CTCPure Deck

The primary strength of this deck is its ability to humanize a complex medical problem. By using "Jack" as a proxy for the patient base, the founders successfully illustrate the frustration and danger of diagnostic delays. The focus on the "two-week recovery" period between failed treatments is a poignant detail that highlights the high stakes of oncology. Additionally, the clear focus on a specific niche—lung cancer—is a smart move for a startup, as it suggests a targeted go-to-market strategy rather than trying to solve all cancers at once.

What is Missing from the CTCPure Deck

The omissions in this deck are extensive and would likely prevent it from passing an initial screening at most venture capital firms. First, there is no Team Slide. In medtech, the credentials of the scientific and management team are paramount. Without knowing who is building the microfluidic solution, the claims of innovation carry little weight. Second, there is no technical validation. There are no charts showing the sensitivity or specificity of their filtration method, nor are there comparisons to the current gold standard of tissue biopsies. Third, the business model is absent. The deck mentions savings for the system but does not explain how CTCPure makes money (e.g., per-test fee, kit sales, or licensing). Finally, the Competition and Ask slides are placeholders , which indicates the deck is unfinished or was used as a teaching exercise rather than a live fundraising tool.

What a Founder Should Copy

Founders can learn from the narrative structure of the early slides. Starting with a patient story (Slide 3) and moving into a logical flowchart of the current system's failures (Slide 6) is an excellent way to build empathy and demonstrate a deep understanding of the problem. This "problem-first" approach ensures that when the solution is finally introduced, its value is already established. Furthermore, the use of a single, massive 'North Star' metric —the $2.3 billion in potential savings—is a good way to grab attention, provided it is backed up by a detailed appendix in a real-world scenario.

Final Analyst Thoughts

The CTCPure deck, as presented, is a conceptual framework rather than a fundable pitch. It identifies a massive, high-value problem in the oncology space but fails to provide the evidence required to prove that its "microfluidic solution" is the right answer. For a biotech startup to be successful in fundraising, it must move beyond storytelling and provide hard data on clinical efficacy, regulatory pathways (FDA/CE Mark), and a clear, quantified request for capital. As it stands, this deck serves as a cautionary tale of what happens when a template is not fully populated with the rigorous data investors demand.